

07-31-03

1632\$

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Application Number	09/887,540
Filing Date	July 6, 2001
First Named Inventor	Robert KLEIN
Art Unit	1632
Examiner Name	Michael C. Wilson
Attorney Docket Number	R-193

Total Number of Pages in This Submission

**RECEIVED**  
AUG 05 2003  
TECH CENTER 1600/2900**ENCLOSURES (Check all that apply)**

- |   |  |  |
|---|--|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input checked="" type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input checked="" type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/<br>Incomplete Application<br><input type="checkbox"/> Response to Missing Parts<br>under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a<br>Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication<br>to a Technology Center (TC)<br><input type="checkbox"/> Appeal Communication to Board<br>of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC<br>(Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input type="checkbox"/> Other Enclosure(s) (please<br>Identify below): |
|---|--|--|

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual	Kelly L. Quast, Reg. No. 52,141
Signature	<i>Kelly L. Quast</i>
Date	July 30, 2003

**CERTIFICATE OF TRANSMISSION/MAILING**I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as ~~mail~~ in an envelope addressed to: Commissioner for Patents, ~~Washington, DC 20231~~ on this date: July 30, 2003**EXPRESS**

ALEXANDRIA, VA 22304-1450

Typed or printed	Don Mixon	Signature	<i>Don Mixon</i>	Date	July 30, 2003
------------------	-----------	-----------	------------------	------	---------------

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ ) 465.00

## Complete if Known

Application Number 09/887,540  
Filing Date July 6, 2001  
First Named Inventor Robert KLEIN  
Examiner Name Michael C. Wils  
Art Unit 1632  
Attorney Docket No. R-193

RECEIVED  
AUG 05 2003

TECH CENTER 1600/2900

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 50-1271  
Deposit Account Name Deltagen, Inc.

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments  
☐ Charge any additional fee(s) during the pendency of this application  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$ )			

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims  - 20\*\* =  X  =   
Independent Claims  - 3\*\* =  X  =   
Multiple Dependent  =

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ )

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	465.00
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ ) 465.00

## SUBMITTED BY

Name (Print/Type) Kelly L. Quast  
Registration No. (Attorney/Agent) 52,141  
Telephone 650-569-5100  
Signature Kelly L. Quast  
Date July 30, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/887,540	06/21/2001	Robert Klein	R-193	5814

7590 01/30/2003

DELTAGEN, INC.  
1003 Hamilton Avenue  
Menlo Park, CA 94025

EXAMINER

WILSON, MICHAEL C

ART UNIT

PAPER NUMBER

1632

DATE MAILED: 01/30/2003

11

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED  
AUG 05 2003  
TECH CENTER 1600/2900

RECEIVED  
FFB - 8 2003  
BY: MDR  
TUESDAY 4-30-03

# Office Action Summary

Application No.

09/887,540

Applicant(s)

KLEIN, ROBERT

Examiner

Michael C. Wilson

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 12 November 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) 1-4 and 13-19 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 5-12 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s) \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☒ Other: *Notice to Comply*.

### DETAILED ACTION

The amendment to Fig. 3B has been entered. Applicants did not file a new Fig. 3A which still does not have a SEQ ID NO. If 3A is the beginning of the sequence and 3B is the end of the sequence, clarification is required either in the drawings or the description of the drawings.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. **The sequence in Fig. 3A does not have a SEQ ID NO.** Applicants must file a "Sequence Listing" accompanied by directions to enter the listing into the specification as an amendment. Applicant also must provide statements regarding sameness and new matter with regards to the CRF and the "Sequence Listing." The instant office action is made as a means of expediting prosecution; however, failure to fully comply with the sequence rules in response to the instant office action will be considered non-responsive.

### *Election/Restrictions*

Applicant's clarification regarding claims 13-16 is acknowledged. Group VI should have been claims 13-15 and Group VII should have been claim 16.

Art Unit: 1632

Applicant's election with traverse of Group IV, claims 8 and 10 in Paper No. 10 is acknowledged.

Groups III (claims 5-7, 9) and V (11, 12) have been recombined with Group IV (8, 10).

Applicant argues that the constructs of Groups I and II have varying scopes but both comprise an LPR5 gene. Applicant's argument is not persuasive. Claim 4 requires two sequences homologous to an LPR5 gene with a marker gene in between which cannot encode LPR5 while claim 1 requires two sequences homologous to an LPR5 gene, which does encompass DNA encoding LPR5. LPR5 knockout constructs and constructs encoding LPR5 are different because they have different structures and different functions. The LPR5 knockout construct does not require the entire LPR5 gene while a construct encoding LPR5 requires the entire LPR5 gene. A search for a construct encoding LPR5 would not result in finding a construct having two LPR5 sequences with a marker sequence in between. A search for a construct having two LPR5 sequences with a marker sequence in between would not necessarily result in finding a construct having the entire LPR5 gene.

Applicant argues that a search of the construct of Group I would produce the cells of Group III and vice versa. Applicant's argument is not persuasive. The cells of Group III do not encode LPR5 and have a knockout construct while the construct Group I causes expression of LPR5 and cannot have a selection marker in-between the two LPR5 sequences as in claim 4.

Art Unit: 1632

Applicant argues a search of Groups I and IV or V would not be undue.

Applicant's argument is not persuasive because the construct encodes LPR5 while the transgenics do not have a construct that encodes LPR5. In fact, the transgenics have a disruption in LPR5.

Applicant argues a search of Groups I and VI would not be undue. Applicant's argument is not persuasive because the construct encodes LPR5 while the cells used in the method have a disruption in LPR5 and do not have a construct encoding LPR5.

Applicant argues a search for the construct of Group I and the modulator of Group VII would not be undue. Applicant's argument is not persuasive because they are materially distinct products. The search for each is mutually exclusive.

Applicant argues a search for the LPR5 knockout construct (Group II) and the search for cells having a disruption in LPR5 (Group III), transgenics having a disruption in LPR5 (Group IV) or methods of using the transgenics or cells (Groups V and VI) would not be undue. Applicant's argument is not persuasive. The construct has a different structure and function than the cells or transgenics. A search for the construct does not necessarily result in finding the cells or transgenics. A search for the construct does not necessarily result in finding the steps of the methods. The construct has materially distinct uses, i.e. to make transgenics or to make cells *in vitro* for testing compounds. Therefore, Group II is patentably distinct from Groups III, IV, V or VI.

Applicant argues a search for the LPR5 knockout construct of Group II and the modulator of Group VII would not be undue. Applicant's argument is not persuasive

because they are materially distinct products. The search for each is mutually exclusive.

Applicant argues a search for cells having a disruption in LPR5 (Group III), transgenics having a disruption in LPR5 (Group IV) or methods of using the transgenics to test compounds (Group V) combined with a search for methods of using the cells to test compounds (Group VI) would not be undue. Applicant's argument is not persuasive. The cells have materially distinct uses, i.e. to make transgenics or to test compounds in vitro. The construct has a different structure and function than the cells or transgenics. A search for the cells or transgenics does not necessarily result in finding the steps of the method of testing compounds using cells. A search for the method of using transgenics does not necessarily result in finding the steps of methods of using the cells in vitro. Therefore, Groups III, IV and V are patentably distinct from Group VI.

Applicant argues a search for cells having a disruption in LPR5 (Group III), transgenics having a disruption in LPR5 (Group IV), methods of making the transgenics (Group IV) or methods of using the transgenics to test compounds (Group V) combined with a search for the modulator of Group VII would not be undue. Applicant's argument is not persuasive. Cells or transgenics are materially distinct from modulators and require different searches, which are mutually exclusive. The search for the method of using transgenics to test compounds does not necessarily result in finding compounds that modulate LPR5 function. The compounds encompassed by Group VII have different uses depending upon their structure.



Applicant argues a search for the method of using cells to identify compounds that modulate LPR5 (Group VI) combined with a search for modulators that modulate LPR5 (Group VII) would not be undue. Applicant's argument is not persuasive. A search for the methods steps does not require searching the modulator, as the method does not necessarily result in finding a compound that modulates LPR5 function. A search for the modulator does not result in finding the method steps because the modulator may be found using a transgenic animal.

The requirement is still deemed proper and is therefore made FINAL.

Claim 1-4 and 13-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 10.

Claims 5-12 are under consideration in the instant office action.

### ***Claim Objections***

Claim 10 is objected to because it is dependent upon claim 1 which is not under consideration.

### ***Specification***

The disclosure is objected to because of the following informalities: pg 50, line 18 and 21 refer to retinal regeneration in context of retinal degeneration on line 20. Retinal

Art Unit: 1632

regeneration is not a species of retinal degeneration. An animal cannot have both retinal regeneration and retinal degeneration. Clarification is required.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 5-12 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for:

- 1) A transgenic mouse whose genome comprises a homozygous disruption of LPR5, wherein said mouse lacks functional LPR5 and wherein said mouse has a phenotype of retinal degeneration,
- 2) A method of making a transgenic mouse having a disruption of LPR5 comprising i) obtaining a mouse ES cell having a disruption of LPR5, ii) introducing said ES cell into a mouse blastocyst, iii) implanting said blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and iv) breeding said chimeric mouse to produce a transgenic mouse whose genome comprises a homozygous disruption of LPR5, wherein said mouse lacks functional LPR5 and wherein said mouse has a phenotype of retinal degeneration, and
- 3) A cell whose genome comprises a homozygous disruption of LPR5 isolated from a transgenic mouse whose genome comprises a homozygous disruption of LPR5,

wherein said mouse lacks functional LPR5 and wherein said mouse has a phenotype of retinal degeneration,

does not reasonably provide enablement for any animal, LPR5 gene, phenotype, cell, disruption, method of making a transgenic or method of using a transgenic as broadly claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Claim 8 is directed toward a transgenic non-human animal having a disruption in an LPR5 gene.

The specification does not enable a transgenic as claimed with a wild-type phenotype. The transgenics throughout the claims do not recite any phenotype and may, therefore, have any phenotype including wild-type phenotype. The specification does not provide any use for a transgenic having a disruption in LPR5 that has a wild-type phenotype. The only disclosed phenotype for the transgenic claimed is one that correlates to a mutation in LRP5 (pg 3, line 10). Therefore, claim 8 should recite a non-wild-type phenotype that correlates to a mutation in LRP5.

The specification does not enable any non-wild-type phenotype other than retinal degeneration. At the time of filing, one of skill in the art filing could not predict the phenotype of a knockout animal (Moreadith, 1997, J. Mol. Med., Vol. 75, pages 208-216; see page 208, column 2, last full paragraph; Aszodi et al., 1998, J. Molecular Med., Vol. 76, pages 238-252; see abstract). Leonard (1995, Immunological Reviews, Vol. 148, pages 98-113) disclosed mice with a disruption in the g<sub>c</sub> gene, which were

intended to be a model for X-linked severe combined immunodeficiency (XSCID), but display a variety of unexpected traits (abstract). These knockout mice were expected to have thymocytes with decreased proliferation in response to stimulation with antibodies, but the thymocytes proliferated normally (page 105, line 7). Moens (1993, Development, Vol. 119, pages 485-499) disclosed that two mutations produced by homologous recombination in two different locations of the N-myc gene produce two different phenotypes in mouse ES cells, one leaky and one null (see abstract). The individual gene of interest and sequences present in the knockout construct are important factors in determining the phenotype of the knockout (Wall, 1996, Theriogenology, Vol. 45, pages 57-68; paragraph bridging pages 61-62). The specification teaches making a transgenic mouse whose genome comprises a homozygous disruption in the mouse LPR5 gene, wherein said mouse lacks functional LPR5 and has retinal degeneration (pg 50). For enablement purposes, it is assumed that "regeneration" on pg 50 should be "degeneration." The results of the open field testing in Fig. 4 and 5 and pg 51 do not correlate to a phenotype because "possible increased anxiety" and "significant hypoactivity" (lines 4 and 7 of pg 51) are not specific to any disease and are not statistically significant because the number of mice tested is not disclosed and the difference observed is not significant. In fact, it cannot be determined what the "2,1," means in "2,1,-/-,Male" or "2,1,+/-,Male" in Fig. 4 and 5. Given the unpredictability in the art taken with the guidance provided in the specification, it would have required one of skill in the art undue experimentation to

determine the phenotype of a knockout other than retinal degeneration. Therefore, claim 8 should be limited to transgenics having a phenotype of retinal degeneration.

The specification does not teach how to make animals having a disruption in an LPR5 gene other than mice. The state of the art at the time of filing was such that embryonic stem (ES) cell technology had only been successful in mice. Wagner (May 1995, Clin. and Experimental Hypertension, Vol. 17, pages 593-605) and Mullins (1996, J. Clin. Invest., Vol. 98, pages S37-S40) taught germline transmission of ES cells has not been demonstrated in species other than mice and the growth of ES cells from species other than mice is unreliable. Wall (1996, cited above) taught transgene expression and the physiological result of such expression in livestock was not always accurately predicted in transgenic mice (page 62, line 7). The specification fails to provide sufficient guidance to make transgenics other than mice by teaching obtaining ES cells in species other than mice. The specification does not teach the nucleic acid sequence of the LPR5 gene in non-mice, non-human species or correlate the LPR5 gene in mice to the LPR5 gene in other species. The specification does not teach how to make knockout animals other than mice or correlate making knockout mice to other species. Therefore, the specification does not provide adequate guidance for one of skill in the art to make a transgenic, non-human animal in any species other than mice.

If the specification did teach how to make transgenics in species other than mice, the specification does not provide adequate correlation between the phenotype obtained in mice to the phenotype obtained in other species. The state of the art at the time of filing was that the phenotype of transgenic mice does not predict the phenotype

Art Unit: 1632

in non-mice species. Models of human diseases have relied on transgenic rats when the development of transgenic mice having the desired phenotype was not feasible. Mullins (1990, Nature, Vol. 344, pg 541-544) produced outbred Sprague-Dawley x WKY rats with hypertension caused by expression of a mouse Ren-2 renin transgene. Hammer (1990, Cell, Vol. 63, pg 1099-1112) describe spontaneous inflammatory disease in inbred Fischer and Lewis rats expressing human class I major histocompatibility allele HLA-B27 and human b<sub>2</sub>-microglobulin transgenes. Both investigations were preceded by the failure to develop human disease-like symptoms in transgenic mice (Mullins, 1989, EMBO, Vol. 8, pg 4065-4072; Taurog, 1988, J. Immunol., Vol. 141, pg 4020-4023) expressing the same transgenes that successfully caused the desired symptoms in transgenic rats. Therefore, the specification does not enable making transgenic having retinal degeneration in species other than mice.

Claims 5-7 are directed toward cells having a disruption in an LRP5 gene. Claims 6 and 7 are limited to a murine cells. Claim 7 is limited to murine ES cells. "Murine" encompasses mice and rats (<http://www.m-w.com/cgi-bin/dictionary?book=Dictionary&va=murine>). Claim 9 is directed toward a cell derived from the transgenic of claim 8. The specification does not provide adequate guidance to make cells as broadly claimed using transgenic animal technology in species other than mice for reasons above. In particular, the specification does not teach how to make murine ES cells as broadly claimed because the specification does not teach rat ES cells or correlate mouse ES cells to rat ES cells. As such, claim 7 should be limited to mouse ES cells. The specification does not teach how to knockout the LRP5 gene in

Art Unit: 1632

non-ES cells or the nucleic acid sequence of non-mouse LRP5 genes. Without such guidance it would require one of skill in the art undue experimentation to make any cell having a disruption in LRP5 as broadly claimed. One of skill would have been limited to mouse ES cells and isolating cells from the transgenic of claim 8.

Claim 10 is directed toward a method of making a transgenic mouse having a disruption in LRP5 using a cell having a construct with two sequences of LRP5, introducing the cell into a blastocyst, implanting the blastocyst into a pseudopregnant mouse which gives birth to chimeric mice, and breeding the chimeric mouse to produce the transgenic mouse. The claim does not require using mouse cells or blastocysts which is considered essential to the invention. The claim does not require using ES cells which is the only type of cell taught in the specification that can be introduced into a blastocyst and result in a chimeric mouse as claimed. The claim does not require a phenotype which is required for reasons cited above. Given the unpredictability in the art taken with the guidance provided in the specification, the cell in a) should be a mouse ES cell, the blastocyst in b) should be a mouse blastocyst, and the transgenic mouse produced should have a genome comprising a homozygous disruption in LRP5, wherein said mouse lacks functional LRP5 and has retinal degeneration.

Claims 11 and 12 are directed toward methods of screening compounds that modulate LRP5 expression and function, respectively, using a transgenic. Claim 11 does not have a disclosed purpose because the

Art Unit: 1632

transgenic does not express LRP5; therefore, expression of LRP5 cannot be determined as in step (c). Step (c) in either claim requires determining whether the expression or function of LRP5 is modulated but does not recite how to make such a determination, and the specification does not teach how to make such a determination. Nor does the specification teach any function of LRP5 that can be of use in the method. While the specification teaches transgenics having retinal degeneration, the specification does not teach how to determine whether a compound modulates retinal degeneration. Such a disclosure is essential to determine compounds that modulate LRP5 expression or function as claimed. What is required is a disclosure of the controls used, how to compare the transgenic animal to the control and when to test for expression and/or function. Without such a disclosure, the specification does not provide adequate guidance for one of skill to make the comparison required to determine compounds that modulate LRP5 expression or function. Finally, the claims should be limited to using transgenic mice whose genomes comprise a homologous disruption in LRP5, wherein said mice lack functional LRP5 and have retinal degeneration for reasons cited above.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:



Art Unit: 1632

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 5-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Rohlmann (1998, J. Clin. Invest., Vol. 101, pg 689-695).

Rohlmann taught making a transgenic mouse having a disruption in LRP made using ES cells (pg 690, col. 1, first full para.). Since the patent office does not have the means to sequence and determine which LRP gene was disrupted by Rohlmann, without evidence to the contrary, Rohlmann disrupted the LRP5 gene as claimed. Rohlmann taught administering adenovirus to the mice and determining the effect on the mice which is equivalent to the methods of claims 11 and 12.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 5-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rohlmann (1998, J. Clin. Invest., Vol. 101, pg 689-695) in view of Hey (1998, Gene, Vol. 216, pg 103-111).

Rohlmann taught making a transgenic mouse having a disruption in LRP made using ES cells (pg 690, col. 1, first full para.). Rohlmann did not

Art Unit: 1632

teach the LRP gene was LRP5 as claimed. Rohlmann taught administering adenovirus to the mice and determining the effect on the mice which is equivalent to the methods of claims 11 and 12.

However, Hey taught the nucleic acid sequence of the mouse LRP5 gene (pg 107).

Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to make a transgenic mouse having a disruption in LRP as taught by Rohlmann wherein the LRP was LRP5 as taught by Hey. One of ordinary skill in the art at the time the invention was made would have been motivated to disrupt the LRP5 gene because Rohlmann taught disrupting LRP genes. One of ordinary skill in the art at the time the invention was made would have been motivated to use the method of Rohlmann to disrupt LRP5 because Hey taught LRP5 is expressed in the liver (pg 108, para. Bridging col. 1-2; Fig. 5A, lane 5) and Rohlmann taught inhibiting expression of LRP specifically in the liver (pg 689, last para.). One of ordinary skill in the art at the time the invention was made would have been motivated to make an LRP5 knockout to determine the function of LRP5 in the liver.

Thus, Applicants' claimed invention, as a whole is prima facie obvious in the absence of evidence to the contrary.

### ***Conclusion***

Art Unit: 1632

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Kato (2002, J. Cell Biol., Vol. 167, Pg 303-314) taught transgenic mice having a disruption in LRP5 had osteoblast proliferation, osteopenia and embryonic eye vascularization (see entire article) which is not disclosed in the instant application. Kato did not teach the mice had retinal degeneration or anxiety as described in the instant application.

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-0120.

Questions of formal matters can be directed to the patent analyst, Dianiece Jacobs, who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-3388.

Questions of a general nature relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

If attempts to reach the examiner, patent analyst or Group receptionist are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051.

The official fax number for this Group is (703) 308-4242.

Michael C. Wilson



MICHAEL C. WILSON  
PATENT EXAMINER

**Notice of References Cited**



Application/Control No.

09/887,540

Applicant(s)/Patent Under  
Reexamination  
Klein, Robert

Examiner

Michael C. Wilson

Art Unit

1632

Page 1 of 4

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**RECEIVED**  
AUG 05 2003  
TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 01/98508	04-2001	US	Brennan	-- --
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Moreadith, 1997, J. Mol. Med., Vol. 75, pages 208-216
	V	Aszodi et al., 1998, J. Molecular Med., Vol. 76, pages 238-252
	W	Leonard (1995, Immunological Reviews, Vol. 148, pages 98-113
	X	Moens (1993, Development, Vol. 119, pages 485-499

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**

Application/Control No.

00/000,000

Applicant(s)/Patent Under  
Reexamination  
<Unknown>

Examiner

Michael C. Wilson

Art Unit

1632

Page 2 of 4

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**RECEIVED**  
AUG 05 2003  
TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Wall, 1996, Theriogenology, Vol. 45, pages 57-68
	V	Wagner, May 1995, Clin. and Experimental Hypertension, Vol. 17, pages 593-605
	W	Mullins, 1996, J. Clin. Invest., Vol. 98, pages S37-S40
	X	Mullins, 1990, Nature, Vol. 344, pg 541-544

\*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**



Application/Control No.

00/000,000

Applicant(s)/Patent Under  
Reexamination  
<Unknown>

Examiner

Michael C. Wilson

Art Unit

1632

Page 3 of 4

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**RECEIVED**  
AUG 05 2003  
TECH CENTER 1600/2900


**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Hammer 1990, Cell, Vol. 63, pg 1099-1112
	V	Mullins, 1989, EMBO, Vol. 8, pg 4065-4072
	W	Taurog, 1988, J. Immunol., Vol. 141, pg 4020-4023
	X	Rohlmann, 1998, J. Clin. Invest., Vol. 101, pg 689-695.

\*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

**Notice of References Cited**

Application/Control No.

09/887,540

Applicant(s)/Patent Under  
Reexamination  
Klein, Robert

Examiner

Michael C. Wilson

Art Unit

1632

Page 4 of 4

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**RECEIVED**  
AUG 05 2003  
TECH CENTER 1600/2900**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Hey, 1998, Gene, Vol. 216, pg 103-111
	V	Kato, 2002, J. Cell Biol., Vol. 167, pg 303-314
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP, § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.



RECEIVED  
AUG 05 2003  
TECH CENTER 1600  
09/887042300

Application No.: 09/887042

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The sequence in Fig. 3A does not have a SEQ ID NO. If it part of SEQ ID NO:1 continued in Fig. 3B, clarification is required in the Figure or in the description of Fig. 3A-3B.

**Applicant Must Provide:**

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**